Sitagliptin increases CXCL10 expression by inhibiting dipeptidyl peptidase IV (DPPIV) and regulates lymphocyte transport to hepatocellular carcinoma (HCC) to promote regression (NCT02650427). This evidence concerns the gene CXCL10 and hepatocellular carcinoma.